Literature DB >> 35896860

Paracrine Factors Released by Stem Cells of Mesenchymal Origin and their Effects in Cardiovascular Disease: A Systematic Review of Pre-clinical Studies.

Nishani S Mabotuwana1,2,3, Lavinia Rech3,4, Joyce Lim1,2,5, Sean A Hardy1,2,3, Lucy A Murtha1,2, Peter P Rainer3,6, Andrew J Boyle7,8,9.   

Abstract

Mesenchymal stem cell (MSC) therapy has gained significant traction in the context of cardiovascular repair, and have been proposed to exert their regenerative effects via the secretion of paracrine factors. In this systematic review, we examined the literature and consolidated available evidence for the "paracrine hypothesis". Two Ovid SP databases were searched using a strategy encompassing paracrine mediated MSC therapy in the context of ischemic heart disease. This yielded 86 articles which met the selection criteria for inclusion in this study. We found that the MSCs utilized in these articles were primarily derived from bone marrow, cardiac tissue, and adipose tissue. We identified 234 individual protective factors across these studies, including VEGF, HGF, and FGF2; which are proposed to exert their effects in a paracrine manner. The data collated in this systematic review identifies secreted paracrine factors that could decrease apoptosis, and increase angiogenesis, cell proliferation, and cell viability. These included studies have also demonstrated that the administration of MSCs and indirectly, their secreted factors can reduce infarct size, and improve left ventricular ejection fraction, contractility, compliance, and vessel density. Furthering our understanding of the way these factors mediate repair could lead to the identification of therapeutic targets for cardiac regeneration.
© 2022. Crown.

Entities:  

Keywords:  Cardiac regeneration; Cardiac repair; Mesenchymal stem cell; Myocardial ischemia; Paracrine; Secreted

Year:  2022        PMID: 35896860     DOI: 10.1007/s12015-022-10429-6

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   6.692


  65 in total

1.  Adult cardiac stem cells are multipotent and support myocardial regeneration.

Authors:  Antonio P Beltrami; Laura Barlucchi; Daniele Torella; Mathue Baker; Federica Limana; Stefano Chimenti; Hideko Kasahara; Marcello Rota; Ezio Musso; Konrad Urbanek; Annarosa Leri; Jan Kajstura; Bernardo Nadal-Ginard; Piero Anversa
Journal:  Cell       Date:  2003-09-19       Impact factor: 41.582

2.  Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI).

Authors:  Birgit Assmus; Volker Schächinger; Claudius Teupe; Martina Britten; Ralf Lehmann; Natascha Döbert; Frank Grünwald; Alexandra Aicher; Carmen Urbich; Hans Martin; Dieter Hoelzer; Stefanie Dimmeler; Andreas M Zeiher
Journal:  Circulation       Date:  2002-12-10       Impact factor: 29.690

3.  C-Kit Positive Cardiac Stem Cells and Bone Marrow-Derived Mesenchymal Stem Cells Synergistically Enhance Angiogenesis and Improve Cardiac Function After Myocardial Infarction in a Paracrine Manner.

Authors:  Luer Bao; Qingshu Meng; Yuan Li; Shengqiong Deng; Zuoren Yu; Zhongmin Liu; Lin Zhang; Huimin Fan
Journal:  J Card Fail       Date:  2017-03-08       Impact factor: 5.712

4.  IL-15: a novel prosurvival signaling pathway in cardiomyocytes.

Authors:  Yerem Yeghiazarians; Norman Honbo; Isabella Imhof; Brandon Woods; Vanessa Aguilera; Jianqin Ye; Andrew J Boyle; Joel S Karliner
Journal:  J Cardiovasc Pharmacol       Date:  2014-05       Impact factor: 3.105

5.  Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation.

Authors:  Jens M Nygren; Stefan Jovinge; Martin Breitbach; Petter Säwén; Wilhelm Röll; Jürgen Hescheler; Jalal Taneera; Bernd K Fleischmann; Sten Eirik W Jacobsen
Journal:  Nat Med       Date:  2004-04-25       Impact factor: 53.440

6.  Isolation and expansion of adult cardiac stem cells from human and murine heart.

Authors:  Elisa Messina; Luciana De Angelis; Giacomo Frati; Stefania Morrone; Stefano Chimenti; Fabio Fiordaliso; Monica Salio; Massimo Battaglia; Michael V G Latronico; Marcello Coletta; Elisabetta Vivarelli; Luigi Frati; Giulio Cossu; Alessandro Giacomello
Journal:  Circ Res       Date:  2004-10-07       Impact factor: 17.367

7.  Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction.

Authors:  Tobias Deuse; Christoph Peter; Paul W M Fedak; Tim Doyle; Hermann Reichenspurner; Wolfram H Zimmermann; Thomas Eschenhagen; William Stein; Joseph C Wu; Robert C Robbins; Sonja Schrepfer
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

8.  Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair.

Authors:  Elisa Avolio; Marco Meloni; Helen L Spencer; Federica Riu; Rajesh Katare; Giuseppe Mangialardi; Atsuhiko Oikawa; Iker Rodriguez-Arabaolaza; Zexu Dang; Kathryn Mitchell; Carlotta Reni; Valeria V Alvino; Jonathan Rowlinson; Ugolini Livi; Daniela Cesselli; Gianni Angelini; Costanza Emanueli; Antonio P Beltrami; Paolo Madeddu
Journal:  Circ Res       Date:  2015-03-23       Impact factor: 17.367

9.  Sca-1+ cardiac stem cells mediate acute cardioprotection via paracrine factor SDF-1 following myocardial ischemia/reperfusion.

Authors:  Chunyan Huang; Hongmei Gu; Qing Yu; Mariuxi C Manukyan; Jeffrey A Poynter; Meijing Wang
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

10.  Safety of intracoronary infusion of 20 million C-kit positive human cardiac stem cells in pigs.

Authors:  Matthew C L Keith; Xian-Liang Tang; Yukichi Tokita; Qian-Hong Li; Shahab Ghafghazi; Joseph Moore Iv; Kyung U Hong; Brandon Elmore; Alok Amraotkar; Brian L Ganzel; Kendra J Grubb; Michael P Flaherty; Gregory Hunt; Bathri Vajravelu; Marcin Wysoczynski; Roberto Bolli
Journal:  PLoS One       Date:  2015-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.